共查询到14条相似文献,搜索用时 187 毫秒
1.
目的 探讨合并低血压的射血分数降低的慢性心力衰竭患者在沙库巴曲缬沙坦药物治疗的基础上联合运动疗法改善心功能的疗效观察。方法 选取60例门诊治疗的心衰症状缓解的慢性心衰患者,血压90/50 mmHg~100/60 mmHg,左室射血分数(LVEF)≤40%,分为运动疗法组:沙库巴曲缬沙坦+运动疗法,对照组:单纯沙库巴曲缬沙坦组。两组患者在原发病治疗的基础上,根据血压情况逐渐滴定沙库巴曲缬沙坦致最大耐受剂量,运动疗法组加用运动训练。结果 与本组治疗前比较,对照组与运动疗法组治疗3个月后6-MWT数值增加,治疗6个月后数值增加量更多(均P<0.01);与本组治疗前比较,对照组收缩压无统计学差异性变化,运动疗法组治疗3个月后收缩压数值增加,治疗6个月后数值增加量更多,(均P<0.01);与本组治疗前比较,对照组舒张压治疗6个月后数值增加(P<0.01),运动疗法组舒张压治疗6个月后数值增加(P<0.01)。与本组治疗3个月后比较,对照组与运动疗法组治疗6个月后6-MWT数值增加(均P<0.01)。与对照组同时间点比较,运动疗法组治疗3个月后6-MWT与收缩压数值增... 相似文献
2.
3.
4.
5.
6.
7.
8.
目的 观察沙库巴曲缬沙坦治疗左室射血分数降低心力衰竭患者的临床疗效。方法 选取云南省第二人民医院心内科2017年11月至2018年4月收治的左室射血分数降低心力衰竭患者180例,随机分为观察组和对照组各90例。两组患者均给予标准化抗心衰治疗,观察组在标准化抗心衰治疗基础上加用沙库巴曲缬沙坦,连续治疗6月。记录两组用药前后左室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左室射血分数(LVEF)、血浆N-末端脑钠肽(NT-proBNP)、6分钟步行试验(6MWT)和明尼苏达心衰量表评分。并记录研究期间住院次数、每次住院天数及不良反应。结果 与对照组比较,沙库巴曲缬沙坦治疗6月后患者LVEDD、LVESD缩小,LVEF增加,NT-proBNP、明尼苏达心衰量表评分降低,6 分钟步行距离延长,住院次数减少,平均住院天数缩短(P<0.05),药物不良反应发生少。结论 沙库巴曲缬沙坦治疗左室射血分数降低心力衰竭患者有效、安全。 相似文献
9.
目的 探讨沙库巴曲缬沙坦对慢性心力衰竭( CHF) 患者运动耐量的影响。方法采用随机数字表法将 80 例 CHF 患者分为对照组和试验组,每组各 40 例。对照组患者给予基础抗 CHF 治疗,试验组患者给予基础抗 CHF 治疗联合沙库巴曲缬沙坦治疗,两组均治疗 6 个月。比较两组患者治疗前后静息心率、血压、BMI、心功能及心肺运动试验结果。结果 治疗后试验组患者左心室舒张末期内径( LVEDD) 、左心室收缩末期内径( LVESD) 、氨基末端脑利尿钠肽前体( NT-proBNP) 水平均低于同期对照组,峰值摄氧量( Peak VO2) 、公斤摄氧量( VO2/ kg) 、峰值心率、峰值氧脉搏( Peak O2) 、无氧阈值( AT) 、代谢当量( MET) 均高于同期对照组( P < 0. 05) 。两组患者治疗后静息收缩压、舒张压、LVEDD、LVESD、NT-proBNP 水平均低于同组治疗前,LVEF 均高于同组治疗前( P <0. 05) 。对照组患者治疗后峰值心率低于同组治疗前,二氧化碳通气当量(... 相似文献
10.
目的评价同心力衰竭(心衰)治疗指南推荐的最佳治疗相比,加用沙库巴曲缬沙坦是否能够更好的改善射血分数保留心功能衰竭患者的症状及预后。方法连续入选2018年3月至2018年9月于解放军总医院第七医学中心就诊的HFpEF患者42例,其中治疗组20例,对照组22例,两组患者均给予心衰治疗指南推荐的最佳药物治疗,其中治疗组加用沙库巴曲缬沙坦100 mg,2/d。随访3月,观察患者NT-proBNP水平、纽约心功能分级及6 min步行试验改善情况,同时评估两组间主要不良心脏事件发生率。结果两组患者基线资料无统计学差异,随访3月,治疗组纽约心功能分级显著优于对照组(P<0.05);治疗组NT-proBNP水平显著低于对照组[(3311.7±781.4)pg/ml vs.(6879.6±1033.5)pg/ml,P<0.001];治疗组6 min步行试验距离显著优于对照组[(550.2±53.2)m vs.(394.2±62.8)m,P<0.001];治疗组共发生MACE事件3例,对照组共发生重点事件9例,治疗组显著优于对照组(P=0.029)。其获益主要来源于因心衰再次住院率显著减少。结论同心衰治疗指南推荐的最佳药物治疗相比,加用沙库巴曲缬沙坦能够更加有效的改善射血分数保留心衰患者的临床症状,降低NT-proBNP水平,并显著减少患者因再次心衰住院的比率。 相似文献
11.
Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized,double‐blind, 8‐week study 下载免费PDF全文
Deanna G. Cheung MD Diego Aizenberg MD Vladimir Gorbunov MD Kudsia Hafeez PhD Chien‐Wei Chen PhD Jack Zhang MD 《Journal of clinical hypertension (Greenwich, Conn.)》2018,20(1):150-158
A majority of patients with hypertension fail to achieve blood pressure (BP) control despite treatment with commonly prescribed drugs. This randomized, double‐blind phase III trial assessed the superiority of sacubitril/valsartan 200 mg (97/103 mg) to continued olmesartan 20 mg in reducing ambulatory systolic BP after 8‐week treatment in patients with mild to moderate essential hypertension uncontrolled with olmesartan 20 mg alone. A total of 376 patients were randomized to receive either sacubitril/valsartan (n = 188) or olmesartan (n = 188). Superior reductions in 24‐hour mean ambulatory systolic BP were observed in the sacubitril/valsartan group vs the olmesartan group (−4.3 mm Hg vs −1.1 mm Hg, P < .001). Reductions in 24‐hour mean ambulatory diastolic BP and pulse pressure and office systolic BP and diastolic BP were significantly greater with sacubitril/valsartan vs olmesartan (P < .014). A greater proportion of patients achieved BP control with sacubitril/valsartan vs olmesartan. The overall incidence of adverse events was comparable between the groups. Compared with continued olmesartan, sacubitril/valsartan was more effective and generally safe in patients with hypertension uncontrolled with olmesartan 20 mg. 相似文献
12.
Impact of systolic blood pressure on the safety and tolerability of initiating and up‐titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study 下载免费PDF全文
Michele Senni John J.V. McMurray Rolf Wachter Hugh F. McIntyre Inder S. Anand Vincenzo Duino Arnab Sarkar Victor Shi Alan Charney 《European journal of heart failure》2018,20(3):491-500
Aims
The TITRATION trial investigated two strategies to initiate and up‐titrate sacubitril/valsartan (LCZ696) to the same target dose, over a condensed (3‐week) or conservative (6‐week) period, in patients with heart failure with reduced ejection fraction (HFrEF) and systolic blood pressure (SBP) of ≥100 mmHg. This post hoc analysis examined the relationship between baseline SBP at screening and achievement of the target dose of sacubitril/valsartan of 97 mg/103 mg (also termed ‘LCZ696 200 mg’) twice per day during the study.Methods and results
Patients (n = 498) were categorized in four groups based on SBP at screening: 100–110 mmHg (n = 70); 111–120 mmHg (n = 93); 121–139 mmHg (n = 168) and ≥140 mmHg (n = 167). Overall, 72.7%, 76.1%, 85.6% and 82.9%, respectively, of patients in these SBP categories achieved and maintained the target dose of sacubitril/valsartan without down‐titration/dose interruption over 12 weeks (‘treatment success’). Compared with patients with SBP of 100–110 mmHg, rates of treatment success among patients in the higher SBP groups [111–120 mmHg (P = 0.96); 121–139 mmHg (P = 0.06) and ≥140 mmHg (P = 0.25)] did not differ significantly. A higher percentage of patients with lower SBP (100–110 mmHg) achieved treatment success with gradual up‐titration (6 weeks) (~80%) than with rapid up‐titration (~69%). Similar findings were observed with regard to ‘tolerability success’ (maintenance of the target dose for at least the final 2 weeks prior to study completion). Hypotension occurred more frequently in patients with lower SBP.Conclusions
The majority of patients (>80%) with SBP of ≥100 mmHg achieved and maintained the target dose of sacubitril/valsartan if the treatment was titrated gradually. These findings suggest that low SBP should not prevent clinicians from considering the initiation of sacubitril/valsartan.13.
《Journal of cardiac failure》2021,27(12):1466-1471
BackgroundHeart failure and sleep-disordered breathing have been increasingly recognized as co-occurring conditions. Their bidirectional relationship warrants investigation into whether heart failure therapy improves sleep and sleep-disordered breathing. We sought to explore the effect of treatment with sacubitril/valsartan on sleep-related endpoints from the AWAKE-HF study.Methods and ResultsAWAKE-HF was a randomized, double-blind study conducted in 23 centers in the United States. Study participants with heart failure with reduced rejection fraction and New York Heart Association class II or III symptoms were randomly assigned to receive treatment with either sacubitril/valsartan or enalapril. All endpoints were assessed at baseline and after 8 weeks of treatment. Portable sleep-monitoring equipment was used to measure the apnea-hypopnea index, including obstructive and central events. Total sleep time, wake after sleep onset and sleep efficiency were exploratory measures assessed using wrist actigraphy.The results were as follows140 patients received treatment in the double-blind phase (sacubitril/valsartan, n = 70; enalapril, n = 70). At baseline, 39% and 40% of patients randomly assigned to receive sacubitril/valsartan or enalapril, respectively, presented with undiagnosed, untreated, moderate-to-severe sleep-disordered breathing (≥ 15 events/h), and nearly all had obstructive sleep apnea. After 8 weeks of treatment, the mean 4% apnea-hypopnea index changed minimally from 16.3/h to 15.2/h in the sacubitril/valsartan group and from 16.8/h to 17.6/h in the enalapril group. Mean total sleep time was long at baseline and decreased only slightly in both treatment groups at week 8 (–14 and –11 minutes for sacubitril/valsartan and enalapril, respectively), with small changes in wake after sleep onset and sleep efficiency in both groups.ConclusionsIn a cohort of patients with heart failure with reduced rejection fraction who met prescribing guidelines for sacubitril/valsartan, one-third had undiagnosed moderate-to-severe obstructive sleep apnea. The addition of sacubitril/valsartan therapy did not significantly improve sleep-disordered breathing or sleep duration or efficiency. Patients who meet indications for treatment with sacubitril/valsartan should be evaluated for sleep-disordered breathing. 相似文献
14.
沙库巴曲缬沙坦是全球近年来慢性心力衰竭(HF)治疗领域具有突破性的创新药物,它是一种血管紧张素受体-脑啡肽酶抑制剂,可同时抑制肾素-血管紧张素-醛固酮系统并调节利钠肽系统。已被证实为目前首个也是唯一一个较标准治疗显著改善HF患者预后的药物,较依那普利能够显著改善射血分数,降低HF患者的死亡风险及再入院率,目前已被各国HF治疗指南推荐为慢性HF的一线治疗药物。后续更多研究表明,沙库巴曲缬沙坦还有逆转心脏重构、保护肾功能、降低血糖等作用,临床应用范围更加广泛,是应该大力推广的抗HF药物。本文将对沙库巴曲缬沙坦治疗HF的最新研究进展做一综述。 相似文献